Shares in sleep treatment specialist ResMed Inc. (CHESS) (ASX: RMD) fell around 6% to $7.40 this morning after the company revealed a profit of US$104.3 million on revenues of US$453.9 million for the quarter ending March 31 2016.

The company declared a quarterly dividend of US3 cents per share.

Once again the standout region was the Americas with revenue up 12% over the prior year’s quarter to US$282.2 million, with revenue in Europe and the rest of the world up 3% on a constant currency basis to US$171.1 million.

The company split out earnings on a non-GAAP accounting basis to deliver a profit of US$112.4 million, up 4% on the prior corresponding quarter. However, the unadjusted (GAAP) profit was flat, which is a result the company blamed on changes in product mix, average selling prices and geographic mix – all of which contributed to falling gross margins.

Large medical device retailers like ResMed or hearing aid manufacturer Cochlear Limited (ASX: COH) rely on the market-leading nature of their products to charge premium prices and grow the all-important profit margins.

Falling margins for medical device or healthcare businesses can spell trouble in the form of competitive pressures and are a traditional ‘sell signal’ for Wall Street analysts schooled to focus on this metric almost above all others.

Today’s share price falls are no big surprise therefore and seem a short-term overreaction when you consider the double-digit revenue growth posted in the US, and fact that adjusted (non-GAAP) earnings lifted 4% over the prior corresponding quarter.

ResMed also cancelled its share buyback over the period, as it needs to save cash after taking its biggest strategic gamble yet with the US$800 million acquisition of US digital healthcare giant Brightree Inc.

Part of the attraction of Brightree is likely its margin-boosting potential and how the acquisition plays out will be a key driver as to the share price’s future direction.

In my opinion today’s price falls are a mild overreaction and selling for $7.40 ResMed is good value for long-term focused investors after a slice of a globally-leading healthcare giant.

Discover the 'new breed' of blue chips that could take your portfolio higher in 2016

These 3 "new breed" top blue chips for 2016 pay fully franked dividends and offer the very real prospect of significant capital appreciation. Click here to learn more.

The report is free! No credit card required.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Tom Richardson owns shares of ResMed Inc..

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.